Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2018 Jan 25;62(2):e01992-17.
doi: 10.1128/AAC.01992-17. Print 2018 Feb.

Comparative In Vitro Activities of Relebactam, Imipenem, the Combination of the Two, and Six Comparator Antimicrobial Agents against 432 Strains of Anaerobic Organisms, Including Imipenem-Resistant Strains

Ellie J C Goldstein  1   2 , Diane M Citron  3 , Kerin L Tyrrell  3 , Eliza Leoncio  3 , C Vreni Merriam  3
Affiliations
Comparative Study

Comparative In Vitro Activities of Relebactam, Imipenem, the Combination of the Two, and Six Comparator Antimicrobial Agents against 432 Strains of Anaerobic Organisms, Including Imipenem-Resistant Strains

Ellie J C Goldstein et al. Antimicrob Agents Chemother. .

Abstract

Relebactam is an important beta-lactamase inhibitor for certain aerobic organisms, but alone it has no antianaerobic activity, with most anaerobes having MICs of ≥32 μg/ml with the exception of a very few strains. There was no enhancement or antagonism of imipenem activity with the addition of relebactam, including activity against imipenem-resistant strains. The relebactam-imipenem combination had excellent overall activity against the anaerobes tested.

Keywords: Bacteroides fragilis; Bacteroides thetaiotaomicron; Bilophila wadsworthia; Desulfovibrio spp.; Eggerthella lenta; F. necrophorum; Parabacteroides goldsteinii; anaerobes; imipenem resistance; relebactam.

PubMed Disclaimer

References

    1. Hirsch EB, Ledesma KR, Chang KT, Schwartz MS, Motyl MR, Tam VH. 2012. In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria. Antimicrob Agents Chemother 56:3753–3757. doi:10.1128/AAC.05927-11. - DOI - PMC - PubMed
    1. Lob SH, Hackel MA, Kazmierczak KM, Young K, Motyl MR, Karlowsky JA, Sahm DF. 2017. In vitro activity of imipenem-relebactam against Gram-negative ESKAPE pathogens isolated by clinical laboratories in the United States in 2015 (Results from the SMART global surveillance program). Antimicrob Agents Chemother 61:e02209-16. doi:10.1128/AAC.02209-16. - DOI - PMC - PubMed
    1. Snydman DR, Jacobus NV, McDermott LA. 2016. In vitro evaluation of the activity of imipenem-relebactam against 451 recent clinical isolates of Bacteroides group and related species. Antimicrob Agents Chemother 60:6393–6397. doi:10.1128/AAC.01125-16. - DOI - PMC - PubMed
    1. Jorgensen JH, Pfaller MA, Carroll KC. 2015. Manual of clinical microbiology, 11th edition. ASM Press, Washington, DC.
    1. Jousimies-Somer HR, Summanen P, Citron DM, Baron EJ, Wexler HM, Finegold SM. 2002. Wadsworth-KTL anaerobic bacteriology manual, 6th ed Star Publishing, Redwood City, CA.

Publication types

MeSH terms